MK-677 ibutamoren,
the complete guide.

MK-677, also known by its generic name ibutamoren (or ibutamoren mesylate), is an orally active growth hormone secretagogue developed by Merck in the 1990s. It was originally investigated as a treatment for growth hormone deficiency, muscle wasting, and osteoporosis. Despite promising Phase II clinical trial data, MK-677 was never approved by the FDA and remains an investigational compound. In the biohacking and bodybuilding communities, it has become one of the most popular compounds for growth hormone optimization due to its oral bioavailability — a significant advantage over injectable peptides and synthetic GH that require subcutaneous or intramuscular injection.

MK-677 ibutamoren works by mimicking ghrelin, the endogenous hunger hormone that signals the pituitary gland to release growth hormone. When MK-677 binds to the ghrelin receptor (GHS-R1a), it triggers a pulsatile release of GH from the anterior pituitary — the same natural secretion pattern the body uses during deep sleep and exercise. This mechanism preserves the body's GH feedback loops, unlike exogenous GH injection which suppresses endogenous production. The result is elevated GH and IGF-1 levels that are sustained for approximately 24 hours per dose, which is why MK-677 is typically dosed once daily.

It's important to note that MK-677 is not a peptide and not a SARM (selective androgen receptor modulator), despite being commonly grouped with both in online discussions. MK-677 is a non-peptide, orally active ghrelin mimetic — a small molecule that activates the same receptor as the peptide ghrelin but can survive gastric digestion and be absorbed through the gut. This oral bioavailability is what separates MK-677 from injectable growth hormone secretagogues like sermorelin, GHRP-6, GHRP-2, and ipamorelin, which must be injected because they are peptides and would be destroyed by stomach acid.

The most significant finding across MK-677 ibutamoren studies is the Nass et al. 2-year trial, which demonstrated that MK-677 maintains its GH-elevating effects without tolerance over extended use — a critical differentiator from some injectable secretagogues where receptor desensitization can reduce efficacy over time. The 24-hour half-life of MK-677 also means a single daily oral dose is sufficient to maintain elevated GH and IGF-1 levels, unlike short-acting injectable secretagogues that require multiple daily injections.

MK-677 works through the growth hormone secretagogue receptor (GHS-R1a), which is the same receptor activated by ghrelin — the endogenous hunger hormone produced primarily in the stomach. When ghrelin or an MK-677 ibutamoren dose binds to GHS-R1a on somatotroph cells in the anterior pituitary, it triggers a signaling cascade that results in the release of stored growth hormone into the bloodstream.

This GH release is pulsatile, not continuous — MK-677 amplifies the natural GH pulses that occur during sleep and in response to exercise, rather than creating a flat, non-physiological GH elevation. This pulsatile pattern is considered safer and more effective than the sustained elevation produced by exogenous GH injection, because the body's negative feedback mechanisms remain intact. The hypothalamus continues to regulate GH output through somatostatin (which inhibits GH release) and GHRH (which stimulates it), and MK-677 works within this existing regulatory framework.

The downstream effect of increased GH is elevated IGF-1 (insulin-like growth factor 1), which is produced primarily in the liver in response to GH signaling. IGF-1 is the primary mediator of GH's anabolic effects — it drives muscle protein synthesis, bone mineralization, collagen production, and cellular repair. In clinical trials, MK-677 ibutamoren consistently increases IGF-1 levels by 39–89% depending on the study population and dosing protocol, with effects sustained for the duration of treatment.

MK-677's interaction with the ghrelin receptor also explains its most common side effect: increased appetite. Ghrelin is the body's primary hunger signal, and MK-677 activates the same receptor — which is why hunger increases are particularly pronounced in the first few weeks of use before the body adapts. See the MK-677 side effects page for a complete breakdown of this and other effects.